Peripheral adenosine infusion versus central access infusion during measurement of FFR

Original title: FFR in the Transradial Era: Will Hand Vein Adenosine Infusion Suffice?A Comparative Study of the Extent, Rapidity, and Stability of Hyperemia From Hand and Femoral Venous Routes of Adenosine Administration. Reference: Peter Scott et al. J Am Coll Cardiol Intv. 2015, online before print.

 

The aim of this study was to compare the administration of adenosine by a path in the back of the hand versus the same drug administration using a central venous access and observe differences to reach peak hyperemia during measurement of fractional flow reserve (FFR). Adenosine is commonly used to achieve maximum hyperemia during the measurement of FFR and the gold standard is administered by a central venous access. With the proliferation of radial access is desirable to have an alternative route around, however, it is unclear whether it is possible to achieve maximum hyperemia using a peripheral access.

Patients scheduled for FFR measurement were selected and administered adenosine sequentially through a 20G cannula into the back of the hand and after a washout of the drug, adenosine was re-administered through an inserter 5 or 6 Fr in the femoral vein. Adenosine was given at 140 ug / kg / min for each access. The interpretation of the data was blind regarding the administration via. Measurements were performed in 84 vessels of 61 patients with a mean value of FFR of 0.85 (0.986 correlation between both accesses). Hyperemia peak time was different, requiring an average of 22 seconds more for peripheral access (63 seconds versus 43 seconds; p <0.0001).

Conclusion

Adenosine infusion during FFR measurement by peripheral access is similar to the administration thereof by central access. This is important from a practical point of view for performing radial access procedures.

Editorial comment

In the FAME study, according to protocol, 140 ug / kg / min of adenosine by femoral venous access were administered and although in daily practice this same dose was often administered peripherally, there was so far, no evidence that it was equivalent. This is an interesting technical detail which increases the comfort of patients receiving radial access in the procedure.

SOLACI

More articles by this author

Plaque Ruptures in Non-Culprit Arteries: Follow-Up With Intravascular Imaging

Plaque rupture remains one of the most important pathophysiological mechanisms in acute coronary syndromes. However, not all ruptures manifest clinically as ischemia, myocardial infarction,...

OCT-Detected High-Risk Plaques Predict Recurrent Events After Myocardial Infarction

After a myocardial infarction (MI), non-culprit lesions are often deferred when they are not flow-limiting (negative FFR). However, these lesions continue to represent an...

Ticagrelor vs Clopidogrel in ACS Patients Receiving DOAC After PCI: More Bleeding Without Ischemic Benefit?

In patients with acute coronary syndrome (ACS) who require direct oral anticoagulation (DOAC) and undergo percutaneous coronary intervention (PCI), current guidelines recommend a dual...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img
Jornadas Guatemala 2026

Recent Articles

SAPIEN 3 TAVI Durability: Ten-Year Follow-Up in Intermediate-Risk Patients

The durability of transcatheter bioprosthetic valves used in TAVI remains one of the key unanswered questions as indications continue to expand toward patients with...

Aneurysm Sac Regression Predicts Better Clinical Outcomes After EVAR?

Aneurysm sac regression following endovascular abdominal aortic aneurysm repair (EVAR) has been proposed as a marker of favorable remodeling and effective aneurysm exclusion. However,...

Inflammation after TAVI: An Emerging Therapeutic Target?

Conduction disturbances and the need for permanent pacemaker implantation remain common complications following TAVI, with an incidence approaching 15%. Although they have traditionally been...